Reid W H
University of Texas Health Science Center, San Antonio, USA.
J Clin Psychiatry. 1999;60 Suppl 1:23-5; discussion 28-30.
A study was conducted in Texas state psychiatric facilities of 299 patients with schizophrenia who were taking clozapine, comparing them with 223 matched controls taking traditional neuroleptics. From 12 months before until 54 months after clozapine was begun, hospital bed days and the associated costs were determined for both groups. The clozapine group had appreciably fewer hospital bed days throughout the study period. Substantially fewer clozapine-treated patients than neuroleptic-treated patients required 180 continuous days of hospitalization during the study. By 48 months after initiation of clozapine, hospital inpatient costs were $27,850/patient/year lower in the clozapine group than in the traditional neuroleptic group. Agranulocytosis occurred in < 1% of patients taking clozapine; all recovered quickly. In a separate study, clozapine therapy was shown to produce a 5-fold decrease in the rate of suicide among patients with schizophrenia. Administration of clozapine appears to lower the overall cost of treating schizophrenia by reducing the costs associated with hospitalizations.
在得克萨斯州的精神病院对299名服用氯氮平的精神分裂症患者进行了一项研究,并将他们与223名服用传统抗精神病药物的匹配对照者进行比较。从开始服用氯氮平前12个月到开始服用氯氮平后54个月,确定了两组的住院天数及相关费用。在整个研究期间,氯氮平组的住院天数明显较少。在研究期间,接受氯氮平治疗的患者中需要连续住院180天的人数明显少于接受抗精神病药物治疗的患者。在开始服用氯氮平48个月后,氯氮平组的医院住院费用比传统抗精神病药物组低27,850美元/患者/年。服用氯氮平的患者中粒细胞缺乏症的发生率<1%;所有患者均迅速康复。在另一项研究中,氯氮平治疗使精神分裂症患者的自杀率降低了5倍。服用氯氮平似乎通过降低与住院相关的费用而降低了治疗精神分裂症的总体成本。